Acutaas Chemicals Ltd

In the Q2 FY27 earnings presentation dated October 27, 2026, Acutaas Chemicals Limited reported revenue of ₹4,369 million, reflecting a 42.7% year-on-year growth. This growth was driven by the Pharmaceutical Intermediates segment, while the Specialty Chemicals segment experienced a decline. The company inaugurated its South Korea manufacturing facility ahead of schedule, enhancing its capacity to produce high-purity chemicals for semiconductor applications. Management revised FY27 revenue guidance upward to around 30% growth from the previous 25% and raised EBITDA margin guidance to 38-40%. Financial metrics showed EBITDA of ₹1,760 million (up 84.6% YoY) and PAT of ₹1,231 million (up 71.4% YoY). For the half-year ended September 30, 2026, revenue reached ₹7,665 million, with EBITDA of ₹2,890 million and PAT of ₹1,981 million. The company noted improved revenue visibility and a robust order pipeline. The balance sheet showed total assets of ₹22,209 million and total liabilities of ₹3,005 million as of H1 FY27. Shareholding as of September 30, 2026, indicated promoters held 32.7%, while FIIs held 22.6% and others 25.3%.

The presentation highlights strong revenue and profit growth, successful operational expansions, and upward revisions to financial guidance.